Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Immunotherapy
Immunotherapy
Immunotherapy Combinations “Raising the Bar”
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer
By
Dr David Spigel
ASCO 2018 Insights
,
Immunotherapy
,
Personalized Medicine
Videos
Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.
Read Article
CAR T-Cell Manufacturing Process Depends on Good Quality T-Cells
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
Web Exclusives
Chimeric antigen receptor (CAR) T-cell therapy has had excellent results in late-stage leukemia and varying degrees of success in some other hematologic cancers, but thus far, solid tumors have not responded to this therapy.
Read Article
The Strengths and Pitfalls of PD-L1 as a Biomarker for Immunotherapy
By
Meg Barbor, MPH
Immunotherapy
,
Personalized Medicine
Web Exclusives
PD-1 and PD-L1 expression on tumor cells is decidedly unique compared with other biomarkers currently used in oncology, and its use has been demonstrated in numerous clinical scenarios. But although the benefits associated with PD-1/PD-L1 targeted therapies have been unprecedented, the risks should not be underestimated.
Read Article
Immune Checkpoint Inhibitors: Test Your Knowledge Level
By
Eileen Koutnik-Fotopoulos
Immunotherapy
,
Personalized Medicine
Web Exclusives
Immune checkpoint inhibitors have changed the treatment landscape for many cancer types. These immunomodulatory antibodies target the PD-1, PD-L1, and CTLA-4 pathways to help restore immune responses against tumors.
Read Article
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
By
Wayne Kuznar
Colorectal Cancer
,
Immunotherapy
,
Solid Tumors
,
Personalized Medicine
Web Exclusives
San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).
Read Article
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes. According to data presented at ASH 2017, 3 approaches are currently being explored.
Read Article
Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A novel, third-generation, oral tyrosine kinase inhibitor (TKI), PF-114 mesylate, has antileukemic activity in heavily pretreated patients with chronic myeloid leukemia (CML), including those with
T315I
mutation, said Jorge E. Cortes, MD, Deputy Chair, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at ASH 2017.
Read Article
CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma
By
Wayne Kuznar
Hematologic Malignancies
,
Immunotherapy
,
Multiple Myeloma
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.
Read Article
CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options. Two studies presented at ASH 2017 provide encouraging news for 2 new drugs, including long-term follow-up of the pivotal ZUMA-1 study of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta), and primary results from the JULIET study of tisagenlecleucel (Kymriah).
Read Article
Page 3 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma